ArticleLasers in medical science2025
Safety of 810 nm photobiomodulation in the developing brain: no evidence of glial reactivity or pro-inflammatory cytokine expression in rats.
Article in Lasers in medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Photobiomodulation (PBM) is an innovative non-invasive light-based technique that uses wavelengths around red to infrared light to stimulate neural activity. Literature has addressed PBM's effectiveness in healthy adult subjects, in several neurological conditions, and also in younger populations. However, there is still a lack of both preclinical and clinical studies that evaluate its safety during early developmental stages, when the brain is still maturing. We explored safety of PBM (810 nm) in young male Wistar rats by examining astrocytes and microglia cells thought GFAP and Iba1 immunohistochemistry, as well as the expression of pro-inflammatory cytokines (Interleukin-6, interleukin-1β and tumour necrosis factor α) through quantitative PCR, both in prefrontal cortex and hippocampus. Under the tested parameters and time point, PBM did not induce detectable glial reactivity or pro-inflammatory cytokine expression. This research highlights the potential use of 810 nm-PBM in the developing brain, providing preliminary evidence that this technique does not induce a neuroinflammatory response, representing an important first step to verifying the beneficial use of this technique without risks in paediatric and adolescence populations. More research is necessary to confirm the safety of PBM for different conditions and employing diverse parameters.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.